Dulasolan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dulasolan

Quick Facts

Property Description
Active ingredient Duloxetine (as the hydrochloride salt)
Form Delayed-release capsule (gastro-resistant)
Pharmacological class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Common use Modulation of mood and chronic pain signals
Origin Synthetic compound

What Type of Medicine is Dulasolan?

Dulasolan is the trade name for the pharmaceutical substance Duloxetine, a synthetic compound classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). It is strictly designated as a prescription-only medicine, identifying it as a potent psychotropic agent that acts directly upon the central nervous system. This dual-acting classification, targeting both serotonin and norepinephrine, is a key feature that distinguishes it from medications acting on only one neurotransmitter, establishing Dulasolan's functional identity.


Composition and Form: Understanding the Delayed-Release Capsule

The active ingredient in Dulasolan is Duloxetine, formulated as a single active ingredient product within a specialized delayed-release capsule designed for oral administration. The capsule utilizes a gastro-resistant coating, a necessary structural feature that prevents the active compound from being prematurely degraded by the acidic environment of the stomach. This engineering ensures the stable and predictable release of Duloxetine only after it has reached the small intestine, providing a continuous supply for systemic absorption and sustained therapeutic effect.


What is the General Purpose of Dulasolan's Action?

The general purpose of Dulasolan's action is to modulate communication within the nervous system by increasing the availability of serotonin and norepinephrine at nerve endings. By slowing the reabsorption (reuptake) of these vital messengers, the drug helps to rebalance and strengthen neural signals. This enhanced and stabilized signaling provides the fundamental basis for Dulasolan’s purpose in helping to regulate emotional stability, thereby impacting mood and modulating the perception of chronic pain signals in typical use scenarios.

Regulatory References

  1. DailyMed Labeling for Duloxetine Delayed-Release Capsules

What side effects are possible with Dulasolan?

Possible Side Effects and Safety Information

The safety profile for Dulasolan (Duloxetine) is defined by classifications and statements established in official regulatory documents, grouping potential effects by their frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their rate of occurrence in clinical use:

  • Very Common (ge 1/10): Nausea, Dry mouth, Headache, and Somnolence.
  • Common (ge 1/100 to <1/10): Includes Dizziness, Insomnia, Constipation, Diarrhoea, Fatigue, and Increased sweating (Hyperhidrosis).
  • Uncommon (ge 1/1,000 to <1/100): May involve Suicidal ideation, Syncope, or Urinary retention.
  • Rare (ge 1/10,000 to <1/1,000): Includes serious documented events such as Serotonin Syndrome and Hepatic failure.

Serious Adverse Reactions and Systemic Concerns

Official labeling highlights several clinically significant, though less frequent, serious adverse reactions, including the risk of Serotonin Syndrome, Severe Skin Reactions (e.g., Stevens-Johnson Syndrome), and potential Hepatotoxicity or fatal liver damage. Safety concerns are grouped by System-Organ-Class (SOC), documenting effects across systems like the Nervous system (e.g., seizures), Vascular system (e.g., hypertension), and Hepato-biliary system.

Population-Specific Safety Notes

The prescribing information contains specific limitations for certain patient populations. The medicine is generally avoided in cases of severe hepatic impairment or severe renal impairment (Creatinine Clearance <30 mL/min). Official data also notes a documented increased risk of suicidal thoughts and behaviors in individuals under 25 years old. Additionally, caution is advised for older adults (ge 65 years) due to an increased risk of falls and hyponatraemia.

Overdose and Emergency Response

Overdose with Dulasolan may present with documented Central Nervous System (CNS) effects, including somnolence, vomiting, and syncope. More severe clinical manifestations that have been reported include seizures and coma. The physiological profile often involves changes in vital functions such as tachycardia, hypotension, or hypertension, reflecting autonomic instability. Fatal outcomes are documented in postmarketing data, primarily in mixed overdoses but also with high doses of duloxetine alone (e.g., 1000 mg or greater).

Immediate medical attention must be sought when overdose is suspected. Life-threatening outcomes, such as Serotonin Syndrome, have been reported and necessitate urgent care. The official regulatory guidance states that treatment should consist of general measures employed in the treatment of any drug overdose, prioritizing adequate airway, oxygenation, and ventilation.

Continuous monitoring of cardiac rhythm and vital signs is required. It is officially documented that no specific antidote is known for Dulasolan overdose, meaning management is focused entirely on providing supportive and symptomatic treatment. Procedural steps like the consideration of activated charcoal or gastric lavage are officially described for limiting absorption.

Therapeutic Uses of Dulasolan

What Dulasolan Treats: Main Uses and Benefits

Dulasolan is considered relevant within therapeutic areas involving heightened emotional and chronic pain symptoms. It is commonly used to help with conditions characterized by periods of heightened symptoms in adults.

This medication is applied in addressing conditions marked by increased physiological stress, such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), and fibromyalgia. It is relevant for easing symptoms related to heightened physiological activity in psychiatric domains, as well as pain symptoms that interfere with daily comfort.

“This approach provides support that helps ease the overall symptom burden during symptomatic periods, supporting the patient during difficult episodes by easing distress.”

Dulasolan is applied in scenarios where additional management of discomfort is required, such as persistent low mood, excessive worry, and nerve pain. It may assist with easing affective and pain symptoms, which plays a role in managing general well-being and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Chronic Discomfort

Property Context Benefit Provided
Symptom Axis Neuropathic and centralized pain Supports the patient by easing distress and may assist with maintaining functional stability.
Symptom Axis Affective and pervasive anxiety Contributes to improved comfort and may assist with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Dulasolan?

Eligibility for Dulasolan (Duloxetine) is defined strictly by official regulatory labeling, focusing on specific health conditions, concurrent treatments, and age.

Absolute Contraindications

Dulasolan must not be used by certain populations due to the risk of serious adverse events, as stated in prescribing information:

  • Patients with severe renal impairment (Creatinine Clearance <30 mL/min) or liver disease resulting in hepatic impairment.
  • Patients with uncontrolled hypertension.
  • Patients taking or who have recently stopped taking a nonselective, irreversible Monoamine Oxidase Inhibitor (MAOI), or certain potent CYP1A2 inhibitors.

Age and Conditional Use

Population Group Eligibility Status
Adults (18+ years) Approved for all labeled uses.
Adolescents (ge 13 years) Approved for Fibromyalgia only.
Children (ge 7 years) Approved for Generalized Anxiety Disorder (GAD) only.
Pregnancy/Lactation Use is conditional; requires a risk-benefit assessment by a healthcare provider.

Use requires special caution in patients with a history of mania, bipolar disorder, seizure disorder, or substantial alcohol use.

What should I know about interactions with other medicines?

The official interaction profile of Dulasolan (Duloxetine) is defined by its metabolic clearance pathways and its pharmacologic activity, leading to specific regulatory prohibitions and restrictions.

Officially Documented Prohibitions and Restrictions

Category Official Regulatory Statement
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is formally prohibited due to the high risk of Serotonin Syndrome. The combination is also contraindicated in patients with chronic liver disease due to reduced drug clearance.
Timing-Based Rules A mandatory 14-day washout period is required when switching between a psychiatric MAOI and Dulasolan.
Exposure-Altering Agents Potent inhibitors of the CYP1A2 enzyme (e.g., Fluvoxamine) are documented to significantly reduce Dulasolan clearance, resulting in a large increase in drug exposure (AUC) and potential need for dose consideration.
Pharmacodynamic Risk Co-administration with other serotonergic agents (e.g., Triptans, SSRIs) increases the risk of Serotonin Syndrome. Combining Dulasolan with drugs that interfere with hemostasis, such as NSAIDs or Warfarin, is documented to increase the risk of abnormal bleeding events.
Substance Interactions Substantial use of alcohol (Ethanol) is documented to increase the risk of hepatotoxicity (liver damage). Co-administration with the supplement St. John's wort or Tryptophan is documented to increase serotonergic risk.
Population Notes Exposure is significantly increased in patients with severe renal impairment (ESRD).

The interaction structure is predominantly based on pharmacokinetic effects on CYP enzymes and pharmacodynamic risk of additive CNS effects, as outlined in government prescribing information.

Mechanism of Action

Dulasolan's core function is to alter signaling dynamics within the Central Nervous System ( CNS) through a specific dual mechanism.


Dual Reuptake Inhibition: Molecular Targets

The drug exerts its initial effect by acting as a high-affinity inhibitor of two key membrane proteins on nerve cells: the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). By blocking these proteins, Dulasolan prevents the rapid reabsorption (reuptake) of the neurotransmitters serotonin ( 5-HT) and norepinephrine ( NE) from the synaptic gap, immediately increasing their concentration and presence to stimulate surrounding receptors.


Central Pathway Modulation: Descending Nociceptive Control

The increased concentration of 5-HT and NE facilitates signaling in the Descending Inhibitory Pain Pathways ( DIPP), which originate in the brainstem and project to the spinal cord. Enhancing activity in these pathways increases the signal intensity of endogenous inhibitory controls over nociception at the spinal level.


Neurochemical Adaptation: Time-Dependent Homeostasis

The full physiological consequence of the mechanism requires a slower, time-dependent adjustment called neurochemical homeostasis, where postsynaptic receptors adapt to the sustained elevation of 5-HT and NE levels. This receptor adaptation leads to the adaptation of central neural circuits to the new monoamine concentration, which defines the time-dependent nature of the mechanism.

Dosage and Administration Information

The administration of Dulasolan, which contains the active ingredient Duloxetine, is governed by the instructions for its oral, delayed-release capsule formulation.

General Administration Rules

Feature Official Guideline
Route of Administration Oral use only.
Timing in Relation to Meals May be taken with or without food.
Capsule Handling Capsule must be swallowed whole; it must not be chewed, crushed, or opened to preserve the essential gastro-resistant coating.

Dosage and Schedule Principles

Treatment is typically administered once daily (QD). The specific starting dose, maintenance dose, and maximum daily dose are established and vary by the approved condition. For most adult conditions, the common maintenance dose is 60 mg once daily. Doses up to 120 mg per day are documented for conditions like Major Depressive Disorder and Generalized Anxiety Disorder.

  • Dose Adjustment: An initial lower dose, such as 30 mg once daily, is a labeled option for one week to allow adjustment before increasing to 60 mg.
  • Discontinuation: The medicine is not to be stopped abruptly. The official procedure requires a gradual dose reduction (tapering) over a period of time, such as at least one to two weeks, when discontinuing treatment.
  • Missed Dose: If a dose is missed, the instruction is to take it as soon as it is remembered. However, two doses must not be taken at the same time.

Physiological Constraints on Use

Usage is restricted in specific patient groups; for instance, administration is avoided in patients with severe renal impairment (creatinine clearance < 30 mL/min) and in those with hepatic insufficiency (chronic liver disease or cirrhosis).

Recent Clinical Evidence

Research Evidence / Overview of Studies

Based on clinical trial data, the primary research for this compound comes from a large, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial.


Phase 3 Trial Results: Study Design

  • Preclinical Hypothesis: Preclinical research has explored the study hypothesis regarding the compound's mechanism, specifically the modulation of a signaling pathway relevant to the condition.
  • Evaluation of Disease Activity: Studies evaluated whether the compound was associated with changes in measures of disease activity in participants with the condition. A major clinical trial examined whether treatment was associated with changes in joint function and pain scores in participants.
  • Timing of Outcome: One study documented that a reported outcome occurred early in the treatment course for some participants.
  • Administration Protocol: The trials evaluated the compound when administered as prescribed by the study protocol.

Long-term Research and Tolerability

Research has also focused on the compound's profile over a prolonged treatment period, as well as its tolerability.

  • Biomarkers: Studies investigated whether this compound was associated with a prolonged change in disease markers. The trials focused on markers related to inflammation and tissue damage.
  • Comparative Data: Direct comparative studies against other treatments remain limited. The majority of research has compared the compound to a placebo.
  • Tolerability Profile: Adverse events reported most frequently in the trials included gastrointestinal disturbances of mild to moderate severity. Clinical trials excluded participants with pre-existing liver conditions. Further research is needed to determine the compound's tolerability profile across a wider range of the adult population.
  • Flare-up Frequency: Studies evaluated whether the compound was associated with a change in the frequency of flare-ups.

Secondary Research and Exploratory Context

  • Co-Administration: Research has not yet established whether co-administration with dietary changes impacts the observed outcomes.
  • Other Conditions: Limited, early-stage studies explored whether the compound was associated with a change in symptoms for two related, but distinct, autoimmune conditions. The findings were mixed and are considered exploratory.

Key Studies & References

  1. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Dulasolan (FAQ)


Q: What is Dulasolan used for besides its main indication?

A: Dulasolan (Duloxetine) has several approved uses beyond mood treatment. Official regulatory documents indicate it is approved for treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). It is also approved for managing chronic pain conditions, specifically Diabetic Peripheral Neuropathic Pain (DPNP), Fibromyalgia (FM), and certain types of Chronic Musculoskeletal Pain.


Q: Does Dulasolan cause weight gain, or is that a common side effect?

A: Official studies show that changes in appetite and weight can occur. Decreased appetite is listed as a common adverse reaction in clinical trials. In the short-term, patients showed a small mean decrease in weight compared to placebo, but long-term studies have noted a small mean weight gain.


Q: Can Dulasolan make you feel more anxious at first?

A: Regulatory documents do not list increased anxiety as a common reaction when starting the medication. However, anxiety and irritability are noted as possible symptoms that may occur if the medicine is discontinued or tapered too quickly. Concerns regarding changes in anxiety level are typically addressed by a healthcare provider.


Q: Can Dulasolan cause dizziness or lightheadedness?

A: Yes, regulatory data reports that dizziness is a common side effect. The medicine can also cause a drop in blood pressure when changing positions, known as orthostatic hypotension, which may lead to feelings of lightheadedness or fainting (syncope). This may occur more frequently when treatment is initiated or when the dose is changed.


Q: Is Dulasolan effective for chronic nerve pain?

A: Official labeling indicates that Dulasolan (Duloxetine) is approved for the management of pain associated with a specific type of chronic nerve pain: diabetic peripheral neuropathic pain (DPNP). Its mechanism helps strengthen the body's natural pain-inhibiting signals.


Q: Can Dulasolan affect blood pressure?

A: Official labeling notes that Dulasolan can cause an increase in blood pressure. Regulatory guidelines stipulate that blood pressure should be monitored before initiation and periodically during treatment. It can also cause a drop in blood pressure when standing (orthostatic hypotension).


Q: Is Dulasolan a controlled substance?

A: According to official regulatory bodies, Dulasolan (Duloxetine) is classified as a prescription-only medicine. However, it is not currently listed as a controlled substance under the U.S. Controlled Substances Act.


Q: How is Dulasolan different from a typical SSRI?

A: Dulasolan is an SNRI (Serotonin and Norepinephrine Reuptake Inhibitor). This means its mechanism works by increasing the availability of both serotonin and norepinephrine in the brain. A typical SSRI (Selective Serotonin Reuptake Inhibitor) primarily focuses on affecting only serotonin.


Q: Is Dulasolan addictive or habit-forming?

A: Regulatory information states that Dulasolan is not associated with abuse potential. However, abruptly stopping the medicine can lead to discontinuation symptoms (such as dizziness, headache, or anxiety). For this reason, gradual dose reduction (tapering) is the required procedure when treatment is discontinued.


Q: Can Dulasolan affect my driving ability?

A: Regulatory warning information cautions that Dulasolan may impair judgment, thinking, or motor skills, and it has been associated with sedation. Patients should use care when operating hazardous machinery, including driving, until the effects of the medication are known.


Q: How does Dulasolan compare to older medications for the same condition?

A: Clinical trials for Dulasolan primarily established its effectiveness by comparing it against a placebo (an inactive treatment). Direct comparative studies against other older medications for the same conditions are limited, according to official data.


Q: Is Dulasolan known to cause sexual side effects?

A: Yes, official regulatory documents indicate that sexual side effects have been reported with Dulasolan use. These may include a decrease in libido (sexual desire), difficulty achieving orgasm, and erectile dysfunction in men.


Q: Does Dulasolan help with anxiety symptoms?

A: Yes, Dulasolan (Duloxetine) is officially approved for the management of Generalized Anxiety Disorder (GAD) in adults, adolescents, and children. Its mechanism helps stabilize mood and anxiety signals.


Q: What kind of monitoring (like blood tests) is needed while on Dulasolan?

A: Regulatory information indicates that blood pressure is typically checked before starting and regularly throughout therapy. Liver enzyme levels are also monitored, and the medicine is typically discontinued if signs of clinically significant liver dysfunction appear.


Q: Is Dulasolan a newer or older medication?

A: Dulasolan (Duloxetine) was initially approved for medical use by the major regulatory bodies in the United States and the European Union in 2004. This places it among the more established medications in its class.


Q: Why is Dulasolan sometimes used for conditions that aren't primarily mood-related?

A: Dulasolan is approved for conditions like fibromyalgia and chronic pain because its dual action on serotonin and norepinephrine also works in the nervous system to strengthen the body's natural descending inhibitory pain pathways. This helps modulate and reduce the perception of chronic pain signals.


Q: Are there studies on Dulasolan's efficacy in diverse populations?

A: Official regulatory data addresses the use of Dulasolan in specific populations. This includes examining safety and effectiveness in pediatric patients, older adults (geriatric patients), and individuals with pre-existing kidney or liver impairment.


Q: Can Dulasolan cause changes in appetite?

A: Yes, official data from clinical trials lists decreased appetite as a common adverse reaction reported by patients taking Dulasolan.

How should Dulasolan be stored and disposed of?

Storage and Disposal Requirements for Dulasolan

Dulasolan (duloxetine delayed-release capsules) must be stored under specific conditions to maintain its effectiveness, as defined by regulatory standards.


Storage Conditions

The medicine requires storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept in its original container or blister packaging. To preserve the integrity of the delayed-release formulation, the capsules must not be crushed, chewed, or opened.

Safety and Disposal

This medication must always be kept out of the sight and reach of children.

Unused or expired Dulasolan must be disposed of properly following local regulations. The medicine should generally not be flushed down the toilet or poured into a drain, as instructed by official guidelines for proper medicinal waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dulasolan found in:

A-Z Index: